close
MENU
Hot Topic Long reads
Hot Topic Long reads
Investment
3 mins to read

Pacific Edge may take legal action over cancer test blow

A preliminary injunction would allow reimbursement to continue in the US.

Cancer diagnostics company Pacific Edge says it will seek a preliminary injunction in the US if it fails to achieve a timely revision or withdrawal of a decision against reimbursement for its Cxbladder tests.

Novitas, the Medicare Administrative Contractor with jurisdiction for its US laboratory in

Want to read more? It's easy.

Choose your best value subscription option

Student

Exclusive offer for uni students studying at a New Zealand university (valued at $499).
Individual
Group membership
NBR Marketplace

Yearly Premium Online Subscription

NZ$499.00 / yearly

Monthly Premium Online Subscription

NZ$44.95 / monthly

Smartphone Only Subscription

NZ$24.95 / monthly

Premium Group Membership 10 Users

NZ$385+GST / monthly

$38.5 per user - Pay by monthly credit card debit

Premium Group Membership 20 Users

NZ$660+GST / monthly

$33 per user - Pay by monthly credit card debit

Premium Group Membership 50 Users

NZ$1375+GST / monthly

$27.5 per user - Pay by monthly credit card debit

Premium Group Membership 100 Users

NZ$2100+GST / monthly

$21 per user - Pay by monthly credit card debit

Yearly Premium Online Subscription + NBR Marketplace

NZ$499.00 / yearly

Already have an account? Login
Fiona Rotherham Wed, 22 Jan 2025
Contact the Writer: fiona@nbr.co.nz
News tip? Question? Typo? Let us know: editor@nbr.co.nz
© All content copyright NBR. Do not reproduce in any form without permission, even if you have a paid subscription.
Company profile
Powered by: nzx logo
Change:
Price
Previous Close
Turnover
Movement
Volume
Avg Daily Volume
Daily High
Daily Low
52 Week High
52 Week Low
Pacific Edge may take legal action over cancer test blow
Investment,
107483
true